Structure Therapeutics Inc. (GPCR)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Structure Therapeutics: The Amylin Data Changes The Math
Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key catalyst.
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 215,800 | $11.89M | $11.47M | -$426,958 | -3.59% |
 John H. Burbank III Passport Capital LLC | 1.43M | $29.71M | $67.06M | $37.35M | 125.7% |
| MJC Michael J. Cuggino Pacific Heights Asset Management LLC | 800,000 | $21.35M | $43.01M | $21.65M | 101.41% |
| NM Nir Messafi Deep Track Capita LLP | 4.74M | $127.38M | $188.09M | $60.71M | 47.66% |
| MPM Mark P. Mennitt CenterBook Partners LP | 148,030 | $7.58M | $5.88M | -$1.7M | -22.4% |
Structure Therapeutics Inc. (GPCR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Structure Therapeutics Inc. ever had a stock split?
Structure Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Raymond C. Stevens CEO | NASDAQ (NMS) Exchange | 86366E106 CUSIP |
| US Country | 281 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Structure Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the global development and commercialization of novel oral therapeutics for the treatment of chronic diseases that currently lack adequate medical solutions. The company, originally known as ShouTi Inc. before its rebranding, was founded in 2016 and has its headquarters in South San Francisco, California. With a mission to address unmet medical needs, Structure Therapeutics is at the forefront of discovering and developing innovative treatments that can be administered orally, offering potential ease-of-use and improved quality of life for patients suffering from various chronic conditions.
Products and Services
- GSBR-1290
- ANPA-0073
- LTSE-2578
An advanced oral small molecule therapy, GSBR-1290, serves as the company's leading product candidate. This drug is specifically designed as a biased agonist of the glucagon-like-peptide-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR) recognized for its efficacy in the treatment of type-2 diabetes mellitus and obesity. By targeting this validated receptor, GSBR-1290 exemplifies the company's commitment to introducing novel therapeutic options for these widespread and impactful health concerns.
As part of its portfolio targeting GPCRs, Structure Therapeutics is developing ANPA-0073, a biased agonist directed at the apelin receptor, another GPCR. The apelin receptor has been implicated in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterized by a progressive decline in lung function. By focusing on this target, ANPA-0073 is at the cutting edge of research for new treatments aimed at IPF, a condition for which current therapeutic options are limited and the need for innovative solutions is high.
LTSE-2578 represents another facet of the company's dedication to addressing pulmonary and cardiovascular diseases through the development of oral small molecule therapeutics. This investigational compound is a lysophosphatidic acid 1 (LPA1) receptor antagonist, geared towards treating idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic diseases. By targeting the LPA1 receptor, LTSE-2578 is aimed at mitigating fibrotic processes, offering hope for treatments in areas where few options currently exist.
